Flinton Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Flinton Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$253K	Buy	9,212 +336	+4%	+$9.96K	0.01%	617
2019 Q2	$294K	Hold	8,876	–	–	0.01%	611
2019 Q1	$311K	Hold	8,876	–	–	0.01%	586
2018 Q4	$295K	Hold	8,876	–	–	0.01%	565
2018 Q3	$447K	Buy	8,876 +1,624	+22%	+$80.2K	0.01%	518
2018 Q2	$434K	Hold	7,252	–	–	0.01%	460
2018 Q1	$332K	Buy	7,252 +308	+4%	+$12.9K	0.01%	527
2017 Q4	$277K	Buy	6,944 +1,456	+27%	+$57.5K	0.01%	580
2017 Q3	$219K	Buy	5,488 +728	+15%	+$31.5K	0.01%	596
2017 Q2	$205K	Buy	4,760 +2,240	+89%	+$79.7K	0.01%	576
2017 Q1	$79K	Buy	2,520 +252	+11%	+$6.75K	﹤0.01%	675
2016 Q4	$57K	Buy	+2,268	New	+$50.7K	﹤0.01%	696

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

ACM

Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Flinton Capital Management's SUPN Position: Q3 2019 in Review

Flinton Capital Management increased its Supernus Pharmaceuticals (SUPN) stake by 3.8% in Q3 2019, buying an estimated $9.96K and bringing the position to 9,212 shares worth $253K. The position accounts for 0.01% of the portfolio, ranked #617.

Flinton Capital Management first reported a position in SUPN in Q4 2016 and has held it in 12 quarters since. The position peaked at $447K in Q3 2018. 243 funds tracked by Wall St. Rank hold SUPN as of Q3 2019.

Flinton Capital Management held 9,212 shares of Supernus Pharmaceuticals worth $253K as of Q3 2019.
Flinton Capital Management bought 336 Supernus Pharmaceuticals shares in Q3 2019, an estimated $9.96K.
Supernus Pharmaceuticals made up 0.01% of Flinton Capital Management's portfolio in Q3 2019, its #617 holding.
Flinton Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2016 and has held it in 12 quarters since.
Flinton Capital Management's Supernus Pharmaceuticals position peaked at $447K in Q3 2018.
243 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.